Float Short %

8.56

Margin Of Safety %

Put/Call OI Ratio

0.92

EPS Next Q Diff

0.01

EPS Last/This Y

-0.02

EPS This/Next Y

0.65

Price

10.09

Target Price

12.71

Analyst Recom

Performance Q

34.53

Relative Volume

0.93

Beta

1.49

Ticker: ITOS

21 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-07-04	ITOS	10.18	0.83	0.26	23484
2025-07-07	ITOS	10.09	0.83	1.42	23563
2025-07-08	ITOS	10.12	0.84	0.44	23797
2025-07-09	ITOS	10.23	0.84	2.65	23913
2025-07-10	ITOS	10.22	0.85	1.06	24349
2025-07-11	ITOS	10.27	0.91	4.92	25174
2025-07-14	ITOS	10.34	0.98	0.95	26249
2025-07-15	ITOS	10.3	0.97	0.60	29893
2025-07-16	ITOS	10.28	0.97	82.50	29920
2025-07-17	ITOS	10.26	0.98	0.51	30047
2025-07-18	ITOS	10.27	0.99	0.12	30086
2025-07-21	ITOS	10.14	0.77	0.71	21825
2025-07-22	ITOS	10.1	0.80	2.09	23974
2025-07-23	ITOS	10.11	0.90	73.15	24853
2025-07-24	ITOS	10.13	0.96	2.87	25671
2025-07-25	ITOS	10.18	1.03	10.88	26374
2025-07-28	ITOS	10.12	1.05	0.00	26698
2025-07-29	ITOS	10.12	0.96	7.84	25593
2025-07-30	ITOS	10.12	0.97	0.00	25916
2025-07-31	ITOS	10.14	0.97	0.16	25987
2025-08-01	ITOS	10.1	0.92	20.14	26940
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

21 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-07-04	ITOS	10.18	-342.4	-	-2.97
2025-07-07	ITOS	10.08	-342.4	-	-2.97
2025-07-08	ITOS	10.12	-342.4	-	-2.97
2025-07-09	ITOS	10.23	-342.4	-	-2.97
2025-07-10	ITOS	10.21	-342.4	-	-2.97
2025-07-11	ITOS	10.29	-342.4	-	-2.97
2025-07-14	ITOS	10.35	-342.4	-	-2.97
2025-07-15	ITOS	10.31	-342.4	-	-2.97
2025-07-16	ITOS	10.28	-342.4	-	-2.97
2025-07-17	ITOS	10.26	-342.4	-	-2.97
2025-07-18	ITOS	10.27	-342.4	-	-2.97
2025-07-21	ITOS	10.14	-342.4	-	-2.97
2025-07-22	ITOS	10.11	-342.4	-	-2.97
2025-07-23	ITOS	10.13	-342.4	-	-2.97
2025-07-24	ITOS	10.15	-342.4	-	-2.97
2025-07-25	ITOS	10.17	-342.4	-	-3.34
2025-07-28	ITOS	10.12	-358.3	-	-3.34
2025-07-29	ITOS	10.11	-358.3	-	-3.34
2025-07-30	ITOS	10.12	-358.3	-	-3.34
2025-07-31	ITOS	10.14	-358.3	-	-3.34
2025-08-01	ITOS	10.09	-358.3	-	-3.34
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-07-04	ITOS	0	32.20	7.53
2025-07-07	ITOS	0	32.21	7.53
2025-07-08	ITOS	0	32.21	7.53
2025-07-09	ITOS	0	32.21	7.53
2025-07-10	ITOS	0	32.21	7.53
2025-07-11	ITOS	0	32.21	7.90
2025-07-14	ITOS	0	32.32	7.90
2025-07-15	ITOS	0	32.32	7.90
2025-07-16	ITOS	0	32.32	7.90
2025-07-17	ITOS	0	32.32	7.90
2025-07-18	ITOS	0	32.32	7.90
2025-07-21	ITOS	0	32.06	7.90
2025-07-22	ITOS	0	32.06	7.90
2025-07-23	ITOS	0	32.06	7.90
2025-07-24	ITOS	0	32.06	7.90
2025-07-25	ITOS	0	32.06	8.56
2025-07-28	ITOS	0	23.58	8.56
2025-07-29	ITOS	0	23.58	8.56
2025-07-30	ITOS	0	23.58	8.56
2025-07-31	ITOS	0	23.58	8.56
2025-08-01	ITOS	0	23.58	8.56
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

-0.8

Avg. EPS Est. Current Quarter

-0.8

Avg. EPS Est. Next Quarter

-0.79

Insider Transactions

Institutional Transactions

23.58

Beta

1.49

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

80.8

Max Drawdown 5-Year %

-89.5

Target Price

12.71

P/E

Forward P/E

PEG

P/S

11.03

P/B

0.69

P/Free Cash Flow

EPS

-3.23

Average EPS Est. Cur. Y

-3.34

EPS Next Y. (Est.)

-2.68

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-373.75

Relative Volume

0.93

Return on Equity vs Sector %

-47

Return on Equity vs Industry %

-28.3

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.37

EBIT Estimation

iTeos Therapeutics, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 173

iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of T-cell immunoreceptor with Ig and ITIM domains (TIGIT), as well as engages the Fc gamma receptor to activate dendritic cells, natural killer cells, T lymphocytes, and macrophages and to promote the release of cytotoxic granules and antibody-dependent cellular cytotoxicity activity. Its product pipeline also includes inupadenant, a next-generation A2AR antagonist program; EOS-984, a small molecule targeting equilibrative nucleoside transporter 1 (ENT1) to reverse immunosuppression and restore T cell proliferation in the tumor microenvironment; and EOS-215, a monoclonal antibody which antagonizes triggering receptor expressed on triggering receptor expressed on myeloid cells 2. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.

stock quote shares ITOS – ITeos Therapeutics Inc Stock Price stock today

news today ITOS – ITeos Therapeutics Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch ITOS – ITeos Therapeutics Inc yahoo finance google finance

stock history ITOS – ITeos Therapeutics Inc invest stock market

stock prices ITOS premarket after hours

ticker ITOS fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: ITOS

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y